Jasper Therapeutics Files 8-K on Warrant and Stock Details
Ticker: JSPRW · Form: 8-K · Filed: Oct 15, 2024 · CIK: 1788028
| Field | Detail |
|---|---|
| Company | Jasper Therapeutics, Inc. (JSPRW) |
| Form Type | 8-K |
| Filed Date | Oct 15, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001, $115.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, warrants, stock-details
Related Tickers: JSPR
TL;DR
Jasper Therapeutics 8-K filed, watch those warrant exercise prices!
AI Summary
Jasper Therapeutics, Inc. filed an 8-K on October 15, 2024, reporting an event that occurred on October 14, 2024. The filing indicates changes related to its common stock and redeemable warrants, specifically concerning the exercise price of its warrants. The company, formerly known as Amplitude Healthcare Acquisition Corp, is incorporated in Delaware and operates in the biological products sector.
Why It Matters
This filing provides updated details on Jasper Therapeutics' capital structure, which could impact investors' understanding of potential dilution and the terms of their investments.
Risk Assessment
Risk Level: low — The filing is a routine 8-K reporting on corporate details and does not appear to disclose significant new risks or material adverse events.
Key Numbers
- 0.0001 — Par Value Per Share (Represents the nominal value of each share of common stock.)
- 11.50 — Warrant Exercise Price (The price at which redeemable warrants can be exercised for one share of common stock.)
Key Players & Entities
- Jasper Therapeutics, Inc. (company) — Registrant
- October 14, 2024 (date) — Earliest event reported
- October 15, 2024 (date) — Filing date
- Amplitude Healthcare Acquisition Corp (company) — Former company name
- Delaware (jurisdiction) — State of incorporation
- 11.50 (dollar_amount) — Warrant exercise price
FAQ
What specific event prompted this 8-K filing on October 14, 2024?
The filing reports on details concerning Jasper Therapeutics, Inc.'s voting common stock and redeemable warrants, including the exercise price of the warrants.
What was Jasper Therapeutics, Inc. previously named?
Jasper Therapeutics, Inc. was formerly known as Amplitude Healthcare Acquisition Corp.
What is the par value of Jasper Therapeutics' common stock?
The par value of Jasper Therapeutics' voting common stock is $0.0001 per share.
What is the exercise price for the redeemable warrants?
The redeemable warrants are exercisable for one share of voting common stock at an exercise price of $11.50.
In which state is Jasper Therapeutics, Inc. incorporated?
Jasper Therapeutics, Inc. is incorporated in Delaware.
Filing Stats: 469 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-10-15 06:03:19
Key Financial Figures
- $0.0001 — tered) Voting Common Stock, par value $0.0001 per share JSPR The Nasdaq Stock Mar
- $115.00 — ng Common Stock at an exercise price of $115.00 JSPRW The Nasdaq Stock Market LLC
Filing Documents
- ea0217519-8k_jasper.htm (8-K) — 28KB
- ea021751901ex99-1_jasper.htm (EX-99.1) — 21KB
- ex99-1_001.jpg (GRAPHIC) — 7KB
- 0001213900-24-087394.txt ( ) — 282KB
- jspr-20241014.xsd (EX-101.SCH) — 4KB
- jspr-20241014_def.xml (EX-101.DEF) — 26KB
- jspr-20241014_lab.xml (EX-101.LAB) — 36KB
- jspr-20241014_pre.xml (EX-101.PRE) — 25KB
- ea0217519-8k_jasper_htm.xml (XML) — 6KB
01. Other Events
Item 8.01. Other Events. On October 14, 2024, Jasper Therapeutics, Inc. (the "Company") issued a press release reporting positive data from the Company's ongoing SPOTLIGHT Phase 1b/2a study of subcutaneous briquilimab in adult participants with cold urticaria or symptomatic dermographism. A copy of the press release is filed herewith as Exhibit 99.1 to this Current Report on Form 8-K.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated October 14, 2024. 104 Cover Page Interactive Data File, formatted in Inline Extensible Business Reporting Language (iXBRL). 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 15, 2024 JASPER THERAPEUTICS, INC. By: /s/ Herb Cross Name: Herb Cross Title: Chief Financial Officer 2